
Release date: 2026-02-28 16:35:13 Article From: Lucius Laos Recommended: 5
Fidaxomicin is an antibiotic used to treat Clostridium difficile infections. Its common side effects include gastrointestinal reactions such as abdominal pain, nausea, and vomiting, as well as blood system abnormalities like anemia and neutropenia. A small number of patients may experience allergic reactions (e.g., rash, itching) or liver function abnormalities. Overall, it is well-tolerated, but monitoring for adverse reactions based on individual circumstances is necessary.
Gastrointestinal discomfort: such as bloating, diarrhea, constipation, and abdominal pain.
Blood system abnormalities: may cause mild anemia or neutropenia (requires regular blood monitoring).
Headache and fatigue: some patients may experience fatigue or dizziness.
Allergic reactions: including rash, itching, and facial swelling; severe cases may cause difficulty breathing (requires immediate discontinuation and medical attention).
Liver function abnormalities: elevated transaminase levels (usually reversible and return to normal after discontinuation).
Intestinal flora imbalance: may worsen diarrhea or lead to infections caused by other pathogens.
Pregnancy and breastfeeding: Currently, there is a lack of safety data; use only after a doctor evaluates the risks.
Hepatic or renal impairment: Dose adjustment or cautious use is required.
Drug interactions: Combining with enzyme inhibitors (e.g., cyclosporine) related to fidaxomicin metabolism may increase the risk of side effects.
Fidaxomicin is a prescription medication and must be taken strictly as prescribed by a doctor. Seek medical attention promptly if the following occur:
Severe abdominal pain, bloody stools, or worsening diarrhea;
Allergic symptoms (e.g., rash, difficulty breathing);
Persistent fatigue or jaundice (may indicate liver function abnormalities).
During treatment, regular blood tests and liver function monitoring are necessary. Do not discontinue or adjust the dosage without consulting a doctor.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1392025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3892024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1372025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1492025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1392025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1612025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1472025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: